Download PDF
Semin Neurol 2016; 36(01): 010-019
DOI: 10.1055/s-0035-1571215
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

The Botulinum Toxin as a Therapeutic Agent: Molecular Structure and Mechanism of Action in Motor and Sensory Systems

Raj Kumar
1   Botulinum Research Center, Institute of Advanced Sciences, Dartmouth, Massachusetts
,
Harkiran Preet Dhaliwal
2   Biomedical Engineering and Biotechnology, University of Massachusetts Dartmouth, Dartmouth, Massachusetts
,
Roshan Vijay Kukreja
1   Botulinum Research Center, Institute of Advanced Sciences, Dartmouth, Massachusetts
,
Bal Ram Singh
1   Botulinum Research Center, Institute of Advanced Sciences, Dartmouth, Massachusetts
3   Prime Bio. Inc., Dartmouth, Massachusetts
› Author Affiliations
Further Information

Publication History

Publication Date:
11 February 2016 (online)

    Permissions and Reprints

Abstract

Botulinum neurotoxin (BoNT) produced by Clostridium botulinum is the most potent molecule known to mankind. Higher potency of BoNT is attributed to several factors, including structural and functional uniqueness, target specificity, and longevity. Although BoNT is an extremely toxic molecule, it is now increasingly used for the treatment of disorders related to muscle hyperactivity and glandular hyperactivity. Weakening of muscles due to peripheral action of BoNT produces a therapeutic effect. Depending on the target tissue, BoNT can block the cholinergic neuromuscular or cholinergic autonomic innervation of exocrine glands and smooth muscles. In recent observations of the analgesic properties of BoNT, the toxin modifies the sensory feedback loop to the central nervous system. Differential effects of BoNT in excitatory and inhibitory neurons provide a unique therapeutic tool. In this review the authors briefly summarize the structure and mechanism of actions of BoNT on motor and sensory neurons to explain its therapeutic effects and future potential.

Keywords

botulinum neurotoxin - sensory neurons - longevity - SNAP-25 - neurotransmitter
 

  • References

  • 1 Sobel J. Botulism. Clin Infect Dis 2005; 41 (8) 1167-1173
    CrossrefPubMedGoogle Scholar
  • 2 Centers for Disease Control (CDC). Botulism. Atlanta, GA: CDC. Available at: http://www.cdc.gov/nczved/divisions/dfbmd/diseases/botulism/ . Accessed April 25, 2014
    PubMedGoogle Scholar
  • 3 Nigam PK, Nigam A. Botulinum toxin. Indian J Dermatol 2010; 55 (1) 8-14
    CrossrefPubMedGoogle Scholar
  • 4 Wenham T, Cohen A. Botulism. Contin Educ Anaesth Crit Care Pain 2008; 8: 21-25
    CrossrefPubMedGoogle Scholar
  • 5 Snipe PT, Sommer H. Studies on botulinus toxin: 3. Acid precipitation of botulinus toxin. J Infect Dis 1928; 43: 152-160
    CrossrefPubMedGoogle Scholar
  • 6 Stefanye D, Schantz EJ, Spero L. Amino acid composition of crystalline botulinum toxin, type A. J Bacteriol 1967; 94 (1) 277-278
    PubMedGoogle Scholar
  • 7 Lamanna C, Spero L, Schantz EJ. Dependence of time to death on molecular size of botulinum toxin. Infect Immun 1970; 1 (4) 423-424
    PubMedGoogle Scholar
  • 8 Schantz EJ. Some chemical and physical properties of Clostridium botulinum toxins in culture. Jpn J Microbiol 1967; 11 (4) 380-383
    CrossrefPubMedGoogle Scholar
  • 9 Scott AB, Rosenbaum A, Collins CC. Pharmacologic weakening of extraocular muscles. Invest Ophthalmol 1973; 12 (12) 924-927
    PubMedGoogle Scholar
  • 10 Scott AB. Botulinum toxin injection into extraocular muscles as an alternative to strabismus surgery. Ophthalmology 1980; 87 (10) 1044-1049
    CrossrefPubMedGoogle Scholar
  • 11 Chen S. Clinical uses of botulinum neurotoxins: current indications, limitations and future developments. Toxins (Basel) 2012; 4 (10) 913-939
    CrossrefPubMedGoogle Scholar
  • 12 Carruthers J, Stubbs HA. Botulinum toxin for benign essential blepharospasm, hemifacial spasm and age-related lower eyelid entropion. Can J Neurol Sci 1987; 14 (1) 42-45
    CrossrefPubMedGoogle Scholar
  • 13 Sattler G. Current and future botulinum neurotoxin type A preparations in aesthetics: a literature review. J Drugs Dermatol 2010; 9 (9) 1065-1071
    PubMedGoogle Scholar
  • 14 Singh BR. Botulinum neurotoxin structure, engineering, and novel cellular trafficking and targeting. Neurotox Res 2006; 9 (2–3) 73-92
    CrossrefPubMedGoogle Scholar
  • 15 Humeau Y, Doussau F, Grant NJ, Poulain B. How botulinum and tetanus neurotoxins block neurotransmitter release. Biochimie 2000; 82 (5) 427-446
    CrossrefPubMedGoogle Scholar
  • 16 Inoue K, Fujinaga Y, Watanabe T , et al. Molecular composition of Clostridium botulinum type A progenitor toxins. Infect Immun 1996; 64 (5) 1589-1594
    PubMedGoogle Scholar
  • 17 Singh BR, Chang TW, Kukreja R, Cai S. The botulinum neurotoxin complex and the role of ancillary proteins. In: Foster KA, , ed. Molecular Aspects of Botulinum Neurotoxin. New York: Springer; 2014: 69-102
    CrossrefGoogle Scholar
  • 18 Singh BR, Foley J, Lafontaine C. Physicochemical and immunological characterization of the type E botulinum neurotoxin binding protein purified from Clostridium botulinum. J Protein Chem 1995; 14 (1) 7-18
    CrossrefPubMedGoogle Scholar
  • 19 East AK, Collins MD. Conserved structure of genes encoding components of botulinum neurotoxin complex M and the sequence of the gene coding for the nontoxic component in nonproteolytic Clostridium botulinum type F. Curr Microbiol 1994; 29 (2) 69-77
    CrossrefPubMedGoogle Scholar
  • 20 Klein AW, Kreyden OP. Storage and dilution of botulinum toxin. In: Boni R, Burg G, Kreyden OP, , eds. Hyperhidrosis and Botulinum Toxin in Dermatology. Basel: Karger Publishers; 2002: 126-130
    CrossrefGoogle Scholar
  • 21 Bryant AM, Davis J, Cai S, Singh BR. Molecular composition and extinction coefficient of native botulinum neurotoxin complex produced by Clostridium botulinum hall A strain. Protein J 2013; 32 (2) 106-117
    CrossrefPubMedGoogle Scholar
  • 22 Carli L, Montecucco C, Rossetto O. Assay of diffusion of different botulinum neurotoxin type a formulations injected in the mouse leg. Muscle Nerve 2009; 40 (3) 374-380
    CrossrefPubMedGoogle Scholar
  • 23 Stone HF, Zhu Z, Thach TQ, Ruegg CL. Characterization of diffusion and duration of action of a new botulinum toxin type A formulation. Toxicon 2011; 58 (2) 159-167
    CrossrefPubMedGoogle Scholar
  • 24 Panicker JN, Muthane UB. Botulinum toxins: pharmacology and its current therapeutic evidence for use. Neurol India 2003; 51 (4) 455-460
    PubMedGoogle Scholar
  • 25 Kim EJ, Ramirez AL, Reeck JB, Maas CS. The role of botulinum toxin type B (Myobloc) in the treatment of hyperkinetic facial lines. Plast Reconstr Surg 2003; 112 (5, Suppl): 88S-93S , discussion 94S–97S
    CrossrefPubMedGoogle Scholar
  • 26 Callaway JE. Botulinum toxin type B (Myobloc): pharmacology and biochemistry. Clin Dermatol 2004; 22 (1) 23-28
    PubMedGoogle Scholar
  • 27 Cai S, Sarkar HK, Singh BR. Enhancement of the endopeptidase activity of botulinum neurotoxin by its associated proteins and dithiothreitol. Biochemistry 1999; 38 (21) 6903-6910
    CrossrefPubMedGoogle Scholar
  • 28 Tang-Liu DD, Aoki KR, Dolly JO , et al. Intramuscular injection of 125I-botulinum neurotoxin-complex versus 125I-botulinum-free neurotoxin: time course of tissue distribution. Toxicon 2003; 42 (5) 461-469
    CrossrefPubMedGoogle Scholar
  • 29 Frevert J, Dressler D. Complexing proteins in botulinum toxin type A drugs: a help or a hindrance?. Biologics 2010; 4: 325-332
    PubMedGoogle Scholar
  • 30 Pickett A, Perrow K. Composition and molecular size of Clostridium botulinum type A toxin-hemagglutinin complex. Protein J 2009; 28 (5) 248-249 , discussion 250–251
    CrossrefPubMedGoogle Scholar
  • 31 Grein S, Mander GJ, Fink K. Stability of botulinum neurotoxin type A, devoid of complexing proteins. The Botulinum J 2011; 2: 49-58
    CrossrefPubMedGoogle Scholar
  • 32 Thirunavukkarasusx N, Ghosal KJ, Kukreja R , et al. Microarray analysis of differentially regulated genes in human neuronal and epithelial cell lines upon exposure to type A botulinum neurotoxin. Biochem Biophys Res Commun 2011; 405 (4) 684-690
    CrossrefPubMedGoogle Scholar
  • 33 Wang L, Sun Y, Yang W, Lindo P, Singh BR. Type A botulinum neurotoxin complex proteins differentially modulate host response of neuronal cells. Toxicon 2014; 82: 52-60
    CrossrefPubMedGoogle Scholar
  • 34 Gu S, Rumpel S, Zhou J , et al. Botulinum neurotoxin is shielded by NTNHA in an interlocked complex. Science 2012; 335 (6071) 977-981
    CrossrefPubMedGoogle Scholar
  • 35 Sagane Y, Miyashita S, Miyata K , et al. Small-angle X-ray scattering reveals structural dynamics of the botulinum neurotoxin associating protein, nontoxic nonhemagglutinin. Biochem Biophys Res Commun 2012; 425 (2) 256-260
    CrossrefPubMedGoogle Scholar
  • 36 Fujinaga Y, Inoue K, Watarai S , et al. Molecular characterization of binding subcomponents of Clostridium botulinum type C progenitor toxin for intestinal epithelial cells and erythrocytes. Microbiology 2004; 150 (Pt 5): 1529-1538
    CrossrefPubMedGoogle Scholar
  • 37 Matsumura T, Sugawara Y, Yutani M , et al. Botulinum toxin A complex exploits intestinal M cells to enter the host and exert neurotoxicity. Nat Commun 2015; 6: 6255
    CrossrefPubMedGoogle Scholar
  • 38 Eisele KH, Fink K, Vey M, Taylor HV. Studies on the dissociation of botulinum neurotoxin type A complexes. Toxicon 2011; 57 (4) 555-565
    CrossrefPubMedGoogle Scholar
  • 39 Lee K, Gu S, Jin L , et al. Structure of a bimodular botulinum neurotoxin complex provides insights into its oral toxicity. PLoS Pathog 2013; 9 (10) e1003690
    CrossrefPubMedGoogle Scholar
  • 40 Montecucco C, Papini E, Schiavo G. Bacterial protein toxins penetrate cells via a four-step mechanism. FEBS Lett 1994; 346 (1) 92-98
    CrossrefPubMedGoogle Scholar
  • 41 Kukreja R, Singh BR. Basic chemistry of botulinum neurotoxins relevant to vaccines, diagnostics, and countermeasures. In: Balali-Mood M, Llewellyn L, Singh B-R, , eds. Toxinology: Biological Toxins and Bioterrorism. New York: Springer; 2014: 1-33
    Google Scholar
  • 42 Nishiki T, Kamata Y, Nemoto Y , et al. Identification of protein receptor for Clostridium botulinum type B neurotoxin in rat brain synaptosomes. J Biol Chem 1994; 269 (14) 10498-10503
    PubMedGoogle Scholar
  • 43 Rummel A, Mahrhold S, Bigalke H, Binz T. The HCC-domain of botulinum neurotoxins A and B exhibits a singular ganglioside binding site displaying serotype specific carbohydrate interaction. Mol Microbiol 2004; 51 (3) 631-643
    PubMedGoogle Scholar
  • 44 Dong M, Yeh F, Tepp WH , et al. SV2 is the protein receptor for botulinum neurotoxin A. Science 2006; 312 (5773) 592-596
    CrossrefPubMedGoogle Scholar
  • 45 Dong M, Liu H, Tepp WH, Johnson EA, Janz R, Chapman ER. Glycosylated SV2A and SV2B mediate the entry of botulinum neurotoxin E into neurons. Mol Biol Cell 2008; 19 (12) 5226-5237
    CrossrefPubMedGoogle Scholar
  • 46 Mahrhold S, Strotmeier J, Garcia-Rodriguez C , et al. Identification of the SV2 protein receptor-binding site of botulinum neurotoxin type E. Biochem J 2013; 453 (1) 37-47
    CrossrefPubMedGoogle Scholar
  • 47 Nishiki T, Tokuyama Y, Kamata Y , et al. The high-affinity binding of Clostridium botulinum type B neurotoxin to synaptotagmin II associated with gangliosides GT1b/GD1a. FEBS Lett 1996; 378 (3) 253-257
    CrossrefPubMedGoogle Scholar
  • 48 Rummel A, Eichner T, Weil T , et al. Identification of the protein receptor binding site of botulinum neurotoxins B and G proves the double-receptor concept. Proc Natl Acad Sci U S A 2007; 104 (1) 359-364
    CrossrefPubMedGoogle Scholar
  • 49 Zhang Y, Varnum SM. The receptor binding domain of botulinum neurotoxin serotype C binds phosphoinositides. Biochimie 2012; 94 (3) 920-923
    CrossrefPubMedGoogle Scholar
  • 50 Schiavo G, Matteoli M, Montecucco C. Neurotoxins affecting neuroexocytosis. Physiol Rev 2000; 80 (2) 717-766
    PubMedGoogle Scholar
  • 51 Montal M. Botulinum neurotoxin: a marvel of protein design. Annu Rev Biochem 2010; 79: 591-617
    CrossrefPubMedGoogle Scholar
  • 52 Singh BR, Kumar R, Cai S. Molecular mechanism and effects of Clostridial neurotoxins. In: Kostrzewa RM, ed. Handbook of Neurotoxicity. New York: Springer; 2014: 513-542
    Google Scholar
  • 53 Couesnon A, Shimizu T, Popoff MR. Differential entry of botulinum neurotoxin A into neuronal and intestinal cells. Cell Microbiol 2009; 11 (2) 289-308
    CrossrefPubMedGoogle Scholar
  • 54 Connan C, Popoff MR. Absorption and transport of botulinum neurotoxin. In: Foster KA, , ed. Molecular Aspects of Botulinum Neurotoxin. New York: Springer; 2014: 35 68;
    CrossrefGoogle Scholar
  • 55 Lang T. SNARE proteins and ‘membrane rafts’. J Physiol 2007; 585 (Pt 3): 693-698
    CrossrefPubMedGoogle Scholar
  • 56 de Paiva A, Meunier FA, Molgó J, Aoki KR, Dolly JO. Functional repair of motor endplates after botulinum neurotoxin type A poisoning: biphasic switch of synaptic activity between nerve sprouts and their parent terminals. Proc Natl Acad Sci U S A 1999; 96 (6) 3200-3205
    CrossrefPubMedGoogle Scholar
  • 57 Duchen LW, Strich SJ. The effects of botulinum toxin on the pattern of innervation of skeletal muscle in the mouse. Q J Exp Physiol Cogn Med Sci 1968; 53 (1) 84-89
    PubMedGoogle Scholar
  • 58 Dressler D, Benecke R. Pharmacology of therapeutic botulinum toxin preparations. Disabil Rehabil 2007; 29 (23) 1761-1768
    CrossrefPubMedGoogle Scholar
  • 59 Frevert J. Pharmaceutical, biological and clinical properties of botulinum neurotoxin type A products. Drugs R D 2015; 15 (1) 1-9
    CrossrefPubMedGoogle Scholar
  • 60 Berry MG, Stanek JJ. Botulinum neurotoxin A: a review. J Plast Reconstr Aesthet Surg 2012; 65 (10) 1283-1291
    CrossrefPubMedGoogle Scholar
  • 61 Huang PP. Intrathecal Botulinum Neurotoxin B: Effects on Spinal Primary Afferent Neurotransmitter Release, Inflammatory Nociception and Neuropathic Pain in the Mouse. San Diego, CA: University of California; 2010
    Google Scholar
  • 62 Lawrence GW, Ovsepian SV, Wang J, Aoki KR, Dolly JO. Extravesicular intraneuronal migration of internalized botulinum neurotoxins without detectable inhibition of distal neurotransmission. Biochem J 2012; 441 (1) 443-452
    CrossrefPubMedGoogle Scholar
  • 63 Restani L, Antonucci F, Gianfranceschi L, Rossi C, Rossetto O, Caleo M. Evidence for anterograde transport and transcytosis of botulinum neurotoxin A (BoNT/A). J Neurosci 2011; 31 (44) 15650-15659
    CrossrefPubMedGoogle Scholar
  • 64 Habermann E. 125I-labeled neurotoxin from Clostridium botulinum A: preparation, binding to synaptosomes and ascent to the spinal cord. Naunyn Schmiedebergs Arch Pharmacol 1974; 281 (1) 47-56
    CrossrefPubMedGoogle Scholar
  • 65 Antonucci F, Rossi C, Gianfranceschi L, Rossetto O, Caleo M. Long-distance retrograde effects of botulinum neurotoxin A. J Neurosci 2008; 28 (14) 3689-3696
    CrossrefPubMedGoogle Scholar
  • 66 Kuehn BM. Studies, reports say botulinum toxins may have effects beyond injection site. JAMA 2008; 299 (19) 2261-2263
    CrossrefPubMedGoogle Scholar
  • 67 Restani L, Giribaldi F, Manich M , et al. Botulinum neurotoxins A and E undergo retrograde axonal transport in primary motor neurons. PLoS Pathog 2012; 8 (12) e1003087
    CrossrefPubMedGoogle Scholar
  • 68 Black JD, Dolly JO. Interaction of 125I-labeled botulinum neurotoxins with nerve terminals. I. Ultrastructural autoradiographic localization and quantitation of distinct membrane acceptors for types A and B on motor nerves. J Cell Biol 1986; 103 (2) 521-534
    CrossrefPubMedGoogle Scholar
  • 69 Wiegand H, Erdmann G, Wellhöner HH. 125I-labelled botulinum A neurotoxin: pharmacokinetics in cats after intramuscular injection. Naunyn Schmiedebergs Arch Pharmacol 1976; 292 (2) 161-165
    CrossrefPubMedGoogle Scholar
  • 70 Matak I, Riederer P, Lacković Z. Botulinum toxin's axonal transport from periphery to the spinal cord. Neurochem Int 2012; 61 (2) 236-239
    CrossrefPubMedGoogle Scholar
  • 71 Marino MJ, Terashima T, Steinauer JJ, Eddinger KA, Yaksh TL, Xu Q. Botulinum toxin B in the sensory afferent: transmitter release, spinal activation, and pain behavior. Pain 2014; 155 (4) 674-684
    CrossrefPubMedGoogle Scholar
  • 72 Akaike N, Shin MC, Wakita M , et al. Transsynaptic inhibition of spinal transmission by A2 botulinum toxin. J Physiol 2013; 591 (Pt 4): 1031-1043
    CrossrefPubMedGoogle Scholar
  • 73 Filipović B, Matak I, Bach-Rojecky L, Lacković Z. Central action of peripherally applied botulinum toxin type A on pain and dural protein extravasation in rat model of trigeminal neuropathy. PLoS ONE 2012; 7 (1) e29803
    CrossrefPubMedGoogle Scholar
  • 74 Pavone F, Luvisetto S. Botulinum neurotoxin for pain management: insights from animal models. Toxins (Basel) 2010; 2 (12) 2890-2913
    CrossrefPubMedGoogle Scholar
  • 75 Bossowska A, Majewski M. Botulinum toxin type A-induced changes in the chemical coding of dorsal root ganglion neurons supplying the porcine urinary bladder. Pol J Vet Sci 2012; 15 (2) 345-353
    PubMedGoogle Scholar
  • 76 Verderio C, Grumelli C, Raiteri L , et al. Traffic of botulinum toxins A and E in excitatory and inhibitory neurons. Traffic 2007; 8 (2) 142-153
    CrossrefPubMedGoogle Scholar
  • 77 Frassoni C, Inverardi F, Coco S , et al. Analysis of SNAP-25 immunoreactivity in hippocampal inhibitory neurons during development in culture and in situ. Neuroscience 2005; 131 (4) 813-823
    CrossrefPubMedGoogle Scholar
  • 78 Verderio C, Pozzi D, Pravettoni E , et al. SNAP-25 modulation of calcium dynamics underlies differences in GABAergic and glutamatergic responsiveness to depolarization. Neuron 2004; 41 (4) 599-610
    CrossrefPubMedGoogle Scholar
  • 79 Huang X, Wheeler MB, Kang YH , et al. Truncated SNAP-25 (1-197), like botulinum neurotoxin A, can inhibit insulin secretion from HIT-T15 insulinoma cells. Mol Endocrinol 1998; 12 (7) 1060-1070
    PubMedGoogle Scholar
  • 80 Criado M, Gil A, Viniegra S, Gutiérrez LM. A single amino acid near the C terminus of the synaptosome associated protein of 25 kDa (SNAP-25) is essential for exocytosis in chromaffin cells. Proc Natl Acad Sci U S A 1999; 96 (13) 7256-7261
    CrossrefPubMedGoogle Scholar
  • 81 Grumelli C, Corradini I, Matteoli M, Verderio C. Intrinsic calcium dynamics control botulinum toxin A susceptibility in distinct neuronal populations. Cell Calcium 2010; 47 (5) 419-424
    CrossrefPubMedGoogle Scholar
  • 82 Pozzi D, Condliffe S, Bozzi Y , et al. Activity-dependent phosphorylation of Ser187 is required for SNAP-25-negative modulation of neuronal voltage-gated calcium channels. Proc Natl Acad Sci U S A 2008; 105 (1) 323-328
    CrossrefPubMedGoogle Scholar
  • 83 Kitamura Y, Matsuka Y, Spigelman I , et al. Botulinum toxin type a (150 kDa) decreases exaggerated neurotransmitter release from trigeminal ganglion neurons and relieves neuropathy behaviors induced by infraorbital nerve constriction. Neuroscience 2009; 159 (4) 1422-1429
    CrossrefPubMedGoogle Scholar
  • 84 Durham PL, Cady R, Cady R. Regulation of calcitonin gene-related peptide secretion from trigeminal nerve cells by botulinum toxin type A: implications for migraine therapy. Headache 2004; 44 (1) 35-42 , discussion 42–43
    CrossrefPubMedGoogle Scholar
  • 85 Meng J, Wang J, Lawrence G, Dolly JO. Synaptobrevin I mediates exocytosis of CGRP from sensory neurons and inhibition by botulinum toxins reflects their anti-nociceptive potential. J Cell Sci 2007; 120 (Pt 16): 2864-2874
    CrossrefPubMedGoogle Scholar
  • 86 Bossowska A, Majewski M. Botulinum toxin type A-induced changes in the chemical coding of dorsal root ganglion neurons supplying the porcine urinary bladder. Pol J Vet Sci 2012; 15 (2) 345-353
    PubMedGoogle Scholar
  • 87 Tsui JKC, Eisen A, Stoessl AJ, Calne S, Calne DB. Double-blind study of botulinum toxin in spasmodic torticollis. Lancet 1986; 2 (8501) 245-247
    PubMedGoogle Scholar
  • 88 Göbel H. Botulinum toxin in migraine prophylaxis. J Neurol 2004; 251 (Suppl. 01) I8-I11
    PubMedGoogle Scholar
  • 89 Allam N, Brasil-Neto JP, Brown G, Tomaz C. Injections of botulinum toxin type a produce pain alleviation in intractable trigeminal neuralgia. Clin J Pain 2005; 21 (2) 182-184
    CrossrefPubMedGoogle Scholar
  • 90 Ranoux D, Attal N, Morain F, Bouhassira D. Botulinum toxin type A induces direct analgesic effects in chronic neuropathic pain. Ann Neurol 2008; 64 (3) 274-283
    CrossrefPubMedGoogle Scholar
  • 91 Mahowald ML, Singh JA, Dykstra D. Long term effects of intra-articular botulinum toxin A for refractory joint pain. Neurotox Res 2006; 9 (2–3) 179-188
    CrossrefPubMedGoogle Scholar
  • 92 Jabbari B. Evidence based medicine in the use of botulinum toxin for back pain. J Neural Transm (Vienna) 2008; 115 (4) 637-640
    CrossrefPubMedGoogle Scholar
  • 93 Burstein R, Zhang X, Levy D, Aoki KR, Brin MF. Selective inhibition of meningeal nociceptors by botulinum neurotoxin type A: therapeutic implications for migraine and other pains. Cephalalgia 2014; 34 (11) 853-869
    CrossrefPubMedGoogle Scholar
  • 94 Shimizu T, Shibata M, Toriumi H , et al. Reduction of TRPV1 expression in the trigeminal system by botulinum neurotoxin type-A. Neurobiol Dis 2012; 48 (3) 367-378
    CrossrefPubMedGoogle Scholar
  • 95 Vacca V, Marinelli S, Luvisetto S, Pavone F. Botulinum toxin A increases analgesic effects of morphine, counters development of morphine tolerance and modulates glia activation and μ opioid receptor expression in neuropathic mice. Brain Behav Immun 2013; 32: 40-50
    CrossrefPubMedGoogle Scholar
  • 96 Aoki KR. Evidence for antinociceptive activity of botulinum toxin type A in pain management. Headache 2003; 43 (Suppl. 01) S9-S15
    CrossrefPubMedGoogle Scholar
  • 97 Baulmann J, Spitznagel H, Herdegen T, Unger T, Culman J. Tachykinin receptor inhibition and c-Fos expression in the rat brain following formalin-induced pain. Neuroscience 2000; 95 (3) 813-820
    PubMedGoogle Scholar
  • 98 Cui M, Khanijou S, Rubino J, Aoki KR. Subcutaneous administration of botulinum toxin A reduces formalin-induced pain. Pain 2004; 107 (1–2) 125-133
    CrossrefPubMedGoogle Scholar
  • 99 Dressler D, Bigalke H, Benecke R. Botulinum toxin type B in antibody-induced botulinum toxin type A therapy failure. J Neurol 2003; 250 (8) 967-969
    CrossrefPubMedGoogle Scholar
  • 100 Klein AW. Complications and adverse reactions with the use of botulinum toxin. Semin Cutan Med Surg 2001; 20 (2) 109-120
    CrossrefPubMedGoogle Scholar
  • 101 Baizabal-Carvallo JF. Can the immunological response to botulinum toxin trigger headaches?. Neurotox Res 2015; 27 (1) 69-70
    CrossrefPubMedGoogle Scholar
  • 102 Ray P, Berman JD, Middleton W, Brendle J. Botulinum toxin inhibits arachidonic acid release associated with acetylcholine release from PC12 cells. J Biol Chem 1993; 268 (15) 11057-11064
    PubMedGoogle Scholar
  • 103 Ishida H, Zhang X, Erickson K, Ray P. Botulinum toxin type A targets RhoB to inhibit lysophosphatidic acid-stimulated actin reorganization and acetylcholine release in nerve growth factor-treated PC12 cells. J Pharmacol Exp Ther 2004; 310 (3) 881-889
    CrossrefPubMedGoogle Scholar
  • 104 Coffield JA, Yan X. Neuritogenic actions of botulinum neurotoxin A on cultured motor neurons. J Pharmacol Exp Ther 2009; 330 (1) 352-358
    CrossrefPubMedGoogle Scholar
  • 105 Proietti S, Nardicchi V, Porena M, Giannantoni A. [Botulinum toxin type-A toxin activity on prostate cancer cell lines]. Urologia 2012; 79 (2) 135-141
    CrossrefPubMedGoogle Scholar
  • 106 Bandala C, Perez-Santos JLM, Lara-Padilla E, Delgado Lopez G, Anaya-Ruiz M. Effect of botulinum toxin A on proliferation and apoptosis in the T47D breast cancer cell line. Asian Pac J Cancer Prev 2013; 14 (2) 891-894
    CrossrefPubMedGoogle Scholar
  • 107 Kumar R, Zhou Y, Ghosal K, Cai S, Singh BR. Anti-apoptotic activity of hemagglutinin-33 and botulinum neurotoxin and its implications to therapeutic and countermeasure issues. Biochem Biophys Res Commun 2012; 417 (2) 726-731
    CrossrefPubMedGoogle Scholar
  • 108 Oh SH, Lee Y, Seo YJ , et al. The potential effect of botulinum toxin type A on human dermal fibroblasts: an in vitro study. Dermatol Surg 2012; 38 (10) 1689-1694
    CrossrefPubMedGoogle Scholar
  • 109 Jeftinija SD, Jeftinija KV, Stefanovic G. Cultured astrocytes express proteins involved in vesicular glutamate release. Brain Res 1997; 750 (1–2) 41-47
    CrossrefPubMedGoogle Scholar
  • 110 Alderton JM, Ahmed SA, Smith LA, Steinhardt RA. Evidence for a vesicle-mediated maintenance of store-operated calcium channels in a human embryonic kidney cell line. Cell Calcium 2000; 28 (3) 161-169
    CrossrefPubMedGoogle Scholar
  • 111 Naumann MK, Hamm H, Lowe NJ ; Botox Hyperhidrosis Clinical Study Group. Effect of botulinum toxin type A on quality of life measures in patients with excessive axillary sweating: a randomized controlled trial. Br J Dermatol 2002; 147 (6) 1218-1226
    CrossrefPubMedGoogle Scholar
  • 112 Souayah N, Karim H, Kamin SS, McArdle J, Marcus S. Severe botulism after focal injection of botulinum toxin. Neurology 2006; 67 (10) 1855-1856
    CrossrefPubMedGoogle Scholar
  • 113 Keller JE, Neale EA, Oyler G, Adler M. Persistence of botulinum neurotoxin action in cultured spinal cord cells. FEBS Lett 1999; 456 (1) 137-142
    CrossrefPubMedGoogle Scholar
  • 114 Adler M, Keller JE, Sheridan RE, Deshpande SS. Persistence of botulinum neurotoxin A demonstrated by sequential administration of serotypes A and E in rat EDL muscle. Toxicon 2001; 39 (2–3) 233-243
    CrossrefPubMedGoogle Scholar
  • 115 Meunier FA, Lisk G, Sesardic D, Dolly JO. Dynamics of motor nerve terminal remodeling unveiled using SNARE-cleaving botulinum toxins: the extent and duration are dictated by the sites of SNAP-25 truncation. Mol Cell Neurosci 2003; 22 (4) 454-466
    CrossrefPubMedGoogle Scholar
  • 116 Fernández-Salas E, Steward LE, Ho H , et al. Plasma membrane localization signals in the light chain of botulinum neurotoxin. Proc Natl Acad Sci U S A 2004; 101 (9) 3208-3213
    CrossrefPubMedGoogle Scholar
  • 117 Tsai YC, Maditz R, Kuo CL , et al. Targeting botulinum neurotoxin persistence by the ubiquitin-proteasome system. Proc Natl Acad Sci U S A 2010; 107 (38) 16554-16559
    CrossrefPubMedGoogle Scholar
  • 118 Walsh CT. Posttranslational Modification of Proteins. 1st ed. Englewood, CO: Roberts and Co; 2006
    Google Scholar
  • 119 Ferrer-Montiel AV, Canaves JM, DasGupta BR, Wilson MC, Montal M. Tyrosine phosphorylation modulates the activity of clostridial neurotoxins. J Biol Chem 1996; 271 (31) 18322-18325
    CrossrefPubMedGoogle Scholar
  • 120 Wang J, Zurawski TH, Meng J , et al. A dileucine in the protease of botulinum toxin A underlies its long-lived neuroparalysis: transfer of longevity to a novel potential therapeutic. J Biol Chem 2011; 286 (8) 6375-6385
    CrossrefPubMedGoogle Scholar
  • 121 Ibañez C, Blanes-Mira C, Fernandez-Ballester G, Planells-Cases R, Ferres-Montiel A. Modulation of botulinum neurotoxin A catalytic domain stability by tyrosine phosphorylation. FEBS Lett 2004; 578 (1–2) 121-127
    CrossrefPubMedGoogle Scholar
  • 122 Toth S, Brueggmann EE, Oyler GA, Smith LA, Hines HB, Ahmed SA. Tyrosine phosphorylation of botulinum neurotoxin protease domains. Front Pharmacol 2012; 3: 102
    PubMedGoogle Scholar